Contents
Download PDF
pdf Download XML
111282 Views
18732 Downloads
Share this article
Review Article | Volume 9 Issue 1 (, 2003) | Pages 112 - 122
Department of Cardio-Thoracic Surgery, University of Vienna, Austria.
 ,
 ,
 ,
 ,
 ,
 ,
1
Department of Thoracic and Cardiovascular Surgery, Heart Center North-Rhine Westfalia, Bad Oeynhausen, Germany.
Under a Creative Commons license
PMID : -10678383
Published
Jan. 11, 2000
Abstract

Background and aim of the study: Pericardial valves combine optimal hemodynamic properties with limited durability. To describe the long-term performance of Mitroflow pericardial valves in the aortic position, outcome and risk factors up to 12 years after implantation were analyzed.

Methods: A retrospective study, based on follow up of 1,029 patients who received 1,044 Mitroflow pericardial valves in the aortic position between February 1985 and December 1996, was performed. Follow up was 98.2% complete. Average follow up was 3.79 years. Mean patient age was 75.2+/-6.5 years (range: 27.9-90.9 years). At surgery, 86.3% of patients were aged over 70 years. Among patients, 482 (46.8%) had concomitant operations.

Results: Results (+/- SE) are given for evident and possible (in parentheses) valve-related events; the latter included all reported postoperative strokes and sudden deaths. Actuarial event-free rates after 5 and 10 years respectively were: structural valve deterioration: 99.2+/-0.5% and 77.6+/-4.4%; non-structural valve deterioration: 99.7+/-0.2% and 99.7+/-1.2%; valve-related complications: 95.7+/-0.9% and 73.5+/-4.0% (5 years 90.1+/-1.2%, 10 years 57.0+/-4.3%); endocarditis: 96.6+/-0.8% and 92.6+/-1.6%; explantation: 98.6+/-0.5% and 80.1+/-3.9%; cerebrovascular accident 95.2+/-0.9% and 82.5+/-3.5%; embolism 99.9+/-0.1% and 99.9+/-0.5%; bleeding 99.8+/-0.2% and 99.8+/-1.3%; overall mortality 69.9+/-1.8% and 35.3+/-3.0%; valve-related death 97.5 +/-1.1% and 95.1+/-4.2% (5 years 91.9+/-1.4%, 10 years 76.1+/-3.2%). The 30-day mortality rate was 4.1%. Patients aged 70 years or more with valve diameters of < or =23 mm showed 10-year freedom rates of 85.8+/-4.6% for structural valve degeneration and 95.1+/-1.2% for evident valve-related death. The detailed risk factor analysis showed results that were in accordance with clinical experience.

Conclusion: Long-term results with Mitroflow pericardial valves in the aortic position compare well with those for other widely used bioprostheses, especially in patients aged > or =70 years and with small aortic root diameters (< or =23 mm).

 

 

 

How to cite: Minami, K., Boethig, D., Mirow, N., Kleikamp, G., Koertke, H., Godehardt, E., & Koerfer, R. (2000). Mitroflow pericardial valve prosthesis in the aortic position: an analysis of long-term outcome and prognostic factors. The Journal of heart valve disease9(1), 112–122.

 
Keywords
Recommended Articles
Research Article
Role of Metformin in Modulating Serum Ghrelin Levels in Obesity
Published: 30/12/2023
Download PDF
Read Article
Research Article
Morphometric Analysis of the Human Mitral Valve: A Cadaveric Study
...
Published: 19/08/2025
Download PDF
Read Article
Research Article
Impact of Metformin Therapy on Serum Adiponectin Levels in Obese Individuals
Published: 14/08/2025
Download PDF
Read Article
Research Article
Prospective Study on Functional Outcome of CTEV By Ponseti Method of Cast Application
...
Published: 31/07/2025
Download PDF
Read Article
© Copyright Journal of Heart Valve Disease